References
Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry 1994; 151: 979–86
Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992 Nov 14; 305: 1198–202
British National Formulary No. 33. London: The Pharmaceutical Press, 1997 Mar: 172–81
PDR Generics. 3rd ed. Montvale NJ: Medical Economics, 1997
Davis R, Whittington R, Bryson H. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997 Apr; 53(4): 608–36
A place on the formulary for SSRIs in the treatment of depression. Drug Ther Perspect 1996; 8(6): 13–6
Venlafaxine: another option in major depression. Drug Ther Perspect 1995; 5(12): 1–4
Paroxetine in depression: improved tolerability over TCAs may offset higher acquisition costs. Drug Ther Perspect 1994; 3(5): 5–7
D’Amico MF, Roberts DL, Robinson DS, et al. Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacol Bull 1990; 26(1): 147–50
Marcus RN, Mendels J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiatry 1996; 57 Suppl. 2: 19–23
Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57 Suppl. 2: 46–52
Feiger AD, Bielski RD, Bremner JD, et al. Efficacy of nefazodone in continuation treatment of depression [abstract no. NR371]. 149th Meeting of the American Psychiatric Association; 1996 May 4–9; New York, 168–169.
Anton SF, Robinson DS, Roberts DL, et al. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994; 30(2): 165–9
Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57 Suppl. 2: 31–8
Lader MH. Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry 1996; 57 Suppl. 2: 39–44
Bristol-Myers Squibb. Nefazodone prescribing information. Princeton, New Jersey, USA, 1996
Aronoff GM. Trazodone associated with priapism [letter]. Lancet 1984 Apr 14; 1: 856
von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29 Suppl. 1: 33–44
Revicki DA, Brown RE, Palmer W, et al. Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics 1995 Dec; 8: 524–40
Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacol Bull 1995; 31(2): 249–58
Montgomery SA, Brown RE, Clark M. Economic analysis of treating depression with nefazodone v. imipramine. Br J Psychiatry 1996 Jun; 168:768–71
Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995; 4(4): 261–77
Frank E, Prien RF, Jarrett RB, et al. Conceptualisation and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991; 48: 851–5
Rights and permissions
About this article
Cite this article
Nefazodone: a better tolerated option than TCAs for major depression. Drugs Ther. Perspect 10, 1–7 (1997). https://doi.org/10.2165/00042310-199710080-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199710080-00001